Tetrahydroisoquinoline derivative
First Claim
1. A compound of formula (II), or a pharmacologically acceptable salt thereof:
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to a compound or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect and feeding suppressant effect. The present invention provides a compound represented by the general formula (I), or pharmacologically acceptable salt thereof:
[wherein,
R1 represents a phenylaminocarbonyl group that may be substituted with 1 to 5 group(s) independently selected from Substituent Group A, a benzoxazol-2-yl group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group A, or the like; R2 independently represents a C1-C6 alkyl group; R3 represents a group represented by the formula —C(═O)—O—R4 or the like; R4 represents a hydrogen atom, a C1-C6 alkyl group that may be substituted with 1 to 3 group(s) independently selected from Substituent Group B, or the like; X represents an oxygen atom, a methylene group, or a group represented by the formula —NH—, or the like; L represents a single bond, a methylene group, or the like; . . . represents a single bond or a double bond; m represents 1 or 2; n represents an integer of 0 to 5; Substituent Group A represents a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a C1-C6 alkoxy group, or the like; and Substituent Group B represents a C3-C6 cycloalkyl group, a phenyl group, a carboxyl group, or the like].
2 Citations
41 Claims
-
1. A compound of formula (II), or a pharmacologically acceptable salt thereof:
-
2. The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R is a phenyl group optionally substituted with 1 to 3 groups each independently selected from a halogen atom, a C1-C6 alkyl group, a C1-C6 halogenated alkyl group, a C1-C6 alkoxy group, and a C1-C6 halogenated alkoxy group or a C3-C6 cycloalkyl group.
-
3. The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R is a phenyl group, a 2-fluorophenyl group, a 3-fluorophenyl group, a 3-methylphenyl group, a 3-ethylphenyl group, a 3-methoxyphenyl group, a 3-ethoxyphenyl group, a 4-trifluoromethylphenyl group, a 3-trifluoromethoxyphenyl group, a 3,4-difluorophenyl group, a 2-fluoro-5-methoxyphenyl group, a 2,4,5-trifluorophenyl group, a 3,4,5-trifluorophenyl group or a cyclopentyl group.
-
4. The compound or pharmacologically acceptable salt thereof according to claim 1, wherein R is a phenyl group, a 2-fluorophenyl group, a 3-fluorophenyl group, a 3-methylphenyl group, a 3-ethylphenyl group, a 3-methoxyphenyl group, a 3-ethoxyphenyl group, a 3-trifluoromethoxyphenyl group, a 3,4-difluorophenyl group, a 2-fluoro-5-methoxyphenyl group or a 2,4,5-trifluorophenyl group.
-
5. The compound or pharmacologically acceptable salt thereof according to claim 1, wherein the compound of formula (II) is
trans-6-[3-(2-fluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(3-ethoxy-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(2,4,5-trifluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(3-methoxy-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-(3-phenyl-ureido)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(3-trifluoromethoxy-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(3,4-difluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(2-fluoro-5-methoxy-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(3-fluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-(3-m-tolyl-ureido)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester or trans-6-[3-(3-ethyl-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
6. The compound according to claim 1, wherein the compound of formula (II) is
trans-6-[3-(2-fluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(3-ethoxy-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(2,4,5-trifluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(3-methoxy-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-(3-phenyl-ureido)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(3-trifluoromethoxy-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(3,4-difluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(2-fluoro-5-methoxy-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-[3-(3-fluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester, trans-6-(3-m-tolyl-ureido)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester or trans-6-[3-(3-ethyl-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
7. The compound according to claim 6, wherein the compound is trans-6-[3-(2-fluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
8. The compound according to claim 6, wherein the compound is trans-6-[3-(3-ethoxy-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
9. The compound according to claim 6, wherein the compound is trans-6-[3-(2,4,5-trifluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
10. The compound according to claim 6, wherein the compound is trans-6-[3-(3,4-difluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
11. The compound according to claim 6, wherein the compound is trans-6-[3-(2-fluoro-5-methoxy-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
12. The compound according to claim 6, wherein the compound is trans-6-(3-m-tolyl-ureido)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
13. The compound according to claim 6, wherein the compound is trans-6-[3-(3-ethyl-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
14. The compound according to claim 1, wherein the compound is trans-6-[3-(2-methoxy-5-methyl-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
15. The compound according to claim 1, wherein the compound is trans-6-[3-(5-ethoxy-2-fluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
16. The compound according to claim 1, wherein the compound is trans-6-(3-p-tolyl-ureido)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
17. The compound according to claim 1, wherein the compound is trans-6-(3-o-tolyl-ureido)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
18. The compound according to claim 1, wherein the compound is trans-6-[3-(3,4-dimethyl-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
19. A pharmaceutical composition comprising a compound or pharmacologically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier.
-
20. The pharmaceutical composition according to claim 19, wherein the compound or pharmacologically acceptable salt is trans-6-[3-(2-fluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
21. The pharmaceutical composition according to claim 19, wherein the compound or pharmacologically acceptable salt is trans-6-[3-(2-methoxy-5-methyl-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
22. The pharmaceutical composition according to claim 19, wherein the compound or pharmacologically acceptable salt is trans-6-[3-(2,4,5-trifluoro-phenyl)-ureido]-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
23. The pharmaceutical composition according to claim 19, wherein the compound or pharmacologically acceptable salt is trans-6-(3-p-tolyl-ureido)-3,4-dihydro-1H-isoquinoline-2-carboxylic acid 4-carboxymethyl-cyclohexyl ester.
-
24. A method for treating diabetes comprising administering a pharmacologically effective amount of a compound or pharmacologically acceptable salt thereof according to claim 1 to a warm-blooded animal.
-
25. A method for treating adiposity or obesity comprising administering a pharmacologically effective amount of a compound or pharmacologically acceptable salt thereof according to claim 1 to a warm-blooded animal.
-
26. The method according to claim 24, wherein the warm-blooded animal is a human.
-
27. The method according to claim 25, wherein the warm-blooded animal is a human.
-
28. A method for treating diabetes comprising administering a pharmacologically effective amount of a compound according to claim 7 or pharmacologically acceptable salt thereof to a human.
-
29. A method for treating diabetes comprising administering a pharmacologically effective amount of a compound according to claim 14 or pharmacologically acceptable salt thereof to a human.
-
30. A method for treating diabetes comprising administering a pharmacologically effective amount of a compound according to claim 9 or pharmacologically acceptable salt thereof to a human.
-
31. A method for treating diabetes comprising administering a pharmacologically effective amount of a compound according to claim 16 or pharmacologically acceptable salt thereof to a human.
-
32. A method for treating adiposity or obesity comprising administering a pharmacologically effective amount of a compound according to claim 7 or pharmacologically acceptable salt thereof to a human.
-
33. A method for treating adiposity or obesity comprising administering a pharmacologically effective amount of a compound according to claim 14 or pharmacologically acceptable salt thereof to a human.
-
34. A method for treating adiposity or obesity comprising administering a pharmacologically effective amount of a compound according to claim 9 or pharmacologically acceptable salt thereof to a human.
-
35. A method for treating adiposity or obesity comprising administering a pharmacologically effective amount of a compound according to claim 16 or pharmacologically acceptable salt thereof to a human.
-
36. A method for treating hypertriglyceridemia comprising administering a pharmacologically effective amount of a compound or pharmacologically acceptable salt thereof according to claim 1 to a warm-blooded animal.
-
37. The method according to claim 36, wherein the warm-blooded animal is a human.
-
38. A method for treating hypertriglyceridemia comprising administering a pharmacologically effective amount of a compound according to claim 7 or pharmacologically acceptable salt thereof to a human.
-
39. A method for treating hypertriglyceridemia comprising administering a pharmacologically effective amount of a compound according to claim 14 or pharmacologically acceptable salt thereof to a human.
-
40. A method for treating hypertriglyceridemia comprising administering a pharmacologically effective amount of a compound according to claim 9 or pharmacologically acceptable salt thereof to a human.
-
41. A method for treating hypertriglyceridemia comprising administering a pharmacologically effective amount of a compound according to claim 16 or pharmacologically acceptable salt thereof to a human.
Specification